D.E. Shaw & Co’s Tempest Therapeutics TPST Stock Holding History

D.E. Shaw & Co’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-7	Closed	-$695K	–	3878
2015 Q1	$695K	Buy	+7	New	+$932K	﹤0.01%	2842

Other funds holding TPST

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co's TPST Position: Q3 2018 in Review

D.E. Shaw & Co sold out of Tempest Therapeutics (TPST) in Q3 2018, closing a stake of 42 shares — an estimated $112K sold.

D.E. Shaw & Co first reported a position in TPST in Q1 2015 and held it in 14 quarters. The position peaked at $4.72M in Q2 2015. 35 funds tracked by Wall St. Rank hold TPST as of Q3 2018.

D.E. Shaw & Co reported no remaining Tempest Therapeutics position as of Q3 2018 after selling out during the quarter.
D.E. Shaw & Co sold 42 Tempest Therapeutics shares in Q3 2018, an estimated $112K.
D.E. Shaw & Co first reported a position in Tempest Therapeutics in Q1 2015 and held it in 14 quarters.
D.E. Shaw & Co's Tempest Therapeutics position peaked at $4.72M in Q2 2015.
35 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2018.

Based on D.E. Shaw & Co's 13F filing for Q3 2018, filed 14 Nov 2018.